Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.
Last trade$36.22
Day change-$0.225 (-0.62%)
Day range$35.40 – $38.00
Volume321,267
Market cap$1.25B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.25B
Price / earnings
—
Price / book
1.38×
Price / sales
22.84×
EV / sales
22.12×
EV / EBITDA
-9.29×
Profitability
Earnings per share
-$4.59
Return on assets
-14.35%
Return on equity
-17.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.42×
Quick ratio
10.42×
Cash ratio
0.55×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$234.03M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NKTR, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$10.13M
$10.86M
$21.81M
$11.79M
$11.18M
$10.46M
$29.18M
$24.12M
Cost of revenue
$0
$0
$0
$0
$0
$0
$7.98M
$4.44M
Gross profit
$10.13M
$10.86M
$21.81M
$11.79M
$11.18M
$10.46M
$21.2M
$19.69M
Selling, general and administrative
$12.77M
$13.44M
$11.19M
$16.07M
$17.07M
$24.35M
$17.14M
$18.96M
Research and development
$39.13M
$35.68M
$29.71M
$27.25M
$29.89M
$30.48M
$28.75M
$35.03M
Total operating expenses
$52.47M
$49.92M
$49.47M
$43.46M
$47.41M
$55M
$47.24M
$54.03M
Operating income
-$42.34M
-$39.05M
-$27.67M
-$31.67M
-$36.23M
-$44.54M
-$26.04M
-$34.35M
Interest expense
-$7.21M
-$7.94M
-$9.77M
-$6.05M
-$5.39M
-$4.97M
-$10.15M
-$6.02M
Income before taxes
-$40.62M
-$43.09M
-$34.7M
-$35.02M
-$41.78M
-$46.37M
$7M
-$37.05M
Income taxes
$2K
$64K
$31K
-$33K
-$188K
$52K
-$259K
$9K
Net income
-$40.62M
-$44.9M
-$36.08M
-$35.52M
-$41.59M
-$50.88M
$7.26M
-$37.06M
Net income attributable to common shareholders
-$40.62M
-$44.9M
-$36.08M
-$35.52M
-$41.59M
-$50.88M
$7.26M
-$37.06M
EBITDA
-$41.61M
-$38.11M
-$18.9M
-$31.34M
-$35.57M
-$43.94M
-$24.35M
-$33.31M
Basic earnings per share
-$1.23
-$1.82
-$1.77
-$1.87
-$2.95
-$3.62
$0.52
-$2.66
Diluted earnings per share
-$1.23
-$1.82
-$1.77
-$1.87
-$2.95
-$3.62
$0.52
-$2.66
Recent news
Company coverage with links to the original publishers.
Nektar Therapeutics reported a Q3 2026 loss of $1.63 per share, beating consensus estimates, but revenues fell 20.4% year-over-year to $9.4 million. The company cut full-year 2026 revenue guidance to $38 million from $40-$45 million and reduced R&D spending guidance. All three Phase III ZENITH AD studies for its lead candidate rezpeg are underway, with initial data expected in summer 2028.
Nektar Therapeutics reported a quarterly loss of $1.63 per share, beating the consensus estimate of $2.16 loss by 24.54%, but missed revenue expectations with $9.39 million versus the estimated $10.23 million. The stock has underperformed the S&P 500 by 20.4% year-to-date. Despite the revenue miss, Nektar holds a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends.
Profound Medical is expected to report a quarterly loss of $0.19 per share with revenues of $9.8 million (up 85.3% YoY) for Q3 2026. With a positive Earnings ESP of +15.79% and Zacks Rank #2 (Buy), the company is positioned to likely beat consensus EPS estimates. However, the stock has missed estimates in recent quarters, delivering a -18.18% surprise last quarter.
Nektar Therapeutics is expected to report a year-over-year decline in earnings and lower revenues for Q3 2026. However, the company shows a positive Earnings ESP of +16.13% combined with a Zacks Rank #3 (Hold), suggesting it will likely beat consensus EPS estimates. The company has beaten consensus estimates in 3 of the last 4 quarters, with the most recent quarter delivering a +40.29% surprise.
Nektar Therapeutics (NKTR) initiated two Phase III studies (ZENITH AD-1 and ZENITH AD-2) for rezpeg in atopic dermatitis in July 2026, with top-line data expected mid-2028. The company plans Phase III studies for alopecia areata in early 2027 and expects Type I diabetes data in 2027. Rezpeg, a self-administered injection that activates regulatory T-cells, faces competition from established players like Sanofi/Regeneron's Dupixent. NKTR trades at a valuation discount to the industry with a Zacks Rank #3 (Hold) rating.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.